Use and Misuse of Nomograms for Prostate Cancer Detection Without Consideration of Analytical Differences Between PSA Assays

被引：0
|
作者：
Siemssen, K. [1 ]
Stephan, Carsten [1 ]
Cammann, Henning [1 ]
Jung, Klaus [1 ]
机构：
[1] Charite Univ Med Berlin, Dept Urol, Berlin, Germany
来源：
EUROPEAN JOURNAL OF MEDICAL RESEARCH | 2009年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
873
引用
收藏
页码：116 / 116
页数：1
相关论文
共 50 条
  • [31] Prostate cancer detection in prostate specific antigen (PSA) range 2.0-3.9 ng/ml -: A study without verification bias
    Raaijmakers, R
    De Vries, SH
    Schröder, FH
    JOURNAL OF UROLOGY, 2004, 171 (04): : 475 - 475
  • [32] Use of [-2] pro PSA and phi index for early detection of prostate cancer: A prospective of 452 patients
    Houlgatte, A.
    Vincendeau, S.
    Desfemmes, F.
    Ramirez, J.
    Benoist, N.
    Bensalah, K.
    Durand, X.
    PROGRES EN UROLOGIE, 2012, 22 (05): : 279 - 283
  • [33] PSA TEST IS APPROVED FOR USE IN CONJUNCTION WITH DIGITAL RECTAL EXAMINATION AS AID IN PROSTATE-CANCER DETECTION
    NIGHTINGALE, SL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (15): : 1160 - 1160
  • [34] Use of the Tandem(R) PSA ratio (free/total PSA) in distinguishing between prostate cancer (PCA) and benign prostatic hyperplasia (BPH).
    Southwick, PC
    Catalona, WJ
    Partin, AW
    Ratliff, TL
    Chan, DW
    Walsh, PC
    Subong, ENP
    Kelley, CA
    Gasior, GH
    CLINICAL CHEMISTRY, 1996, 42 (06) : 667 - 667
  • [35] Clinical Use of [-2] proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature
    Abrate, Alberto
    Lughezzani, Giovanni
    Gadda, Giulio Maria
    Lista, Giuliana
    Kinzikeeva, Ella
    Fossati, Nicola
    Larcher, Alessandro
    Dell'Oglio, Paolo
    Mistretta, Francesco
    Buffi, Nicolomaria
    Guazzoni, Giorgio
    Lazzeri, Massimo
    KOREAN JOURNAL OF UROLOGY, 2014, 55 (07) : 436 - 445
  • [36] Transgender and Non -Binary Use of Gender-Affirming Hormone Therapy and Effects on PSA and Prostate Cancer Detection
    Riviere, P.
    Morgan, K. M.
    Deshler, L. N.
    Tibbs, M. D.
    Qiao, E. M.
    Anger, J.
    Salmasi, A.
    Marshall, D. C.
    Sanghvi, P.
    Rose, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S71 - S71
  • [37] Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis
    Roddam, AW
    Duffy, MJ
    Hamdy, FC
    Ward, AM
    Patnick, J
    Price, CP
    Rimmer, J
    Sturgeon, C
    White, P
    Allen, NE
    EUROPEAN UROLOGY, 2005, 48 (03) : 386 - 399
  • [38] Prostate cancer detection and PSA increase after 4 years in Dutch and Japanese males without evidence of disease at initial screening
    Ito, K
    Raaijmakers, R
    Roobol, MJ
    Wildhagen, MF
    Yamanaka, H
    Schröder, FH
    JOURNAL OF UROLOGY, 2004, 171 (04): : 118 - 119
  • [39] Effect of digital rectal examination and flexible cystoscopy on free and total prostate-specific antigen, and the percentage of free prostate-specific antigen -: Differences between two PSA assays
    Rodríguez-Rubio, FI
    Robles, JE
    González, A
    Arocena, J
    Sanz, G
    Díez-Caballero, F
    Martín-Marquina, A
    Berián, JM
    EUROPEAN UROLOGY, 1998, 33 (03) : 255 - 260
  • [40] Doctors' perspectives on PSA testing illuminate established differences in prostate cancer screening rates between Australia and the UK: a qualitative study
    Pickles, Kristen
    Carter, Stacy M.
    Rychetnik, Lucie
    Entwistle, Vikki A.
    BMJ OPEN, 2016, 6 (12):
12345